Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
- 1 December 2017
- journal article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 16 (4), 377-380
- https://doi.org/10.1016/j.clcc.2017.03.017
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Regorafenib for metastatic colorectal cancerThe Lancet, 2013
- Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapyEuropean Radiology, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibBritish Journal of Cancer, 2010
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver MetastasesJAMA, 2009
- Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)Annals of Oncology, 2009
- Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology, 2007
- Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971